Lilly Targets Six Firms Over Unauthorized Weight-Loss Drug Sales
Eli Lilly filed six lawsuits Wednesday against US companies it accuses of illegally selling black-market versions of its experimental obesity drug retatrutide.
The six named defendants are Aesthetic Envy Cosmetic Centers, Astra LLC, Legendary Peptides, Striker Pharmacy, Texas Peptides, and Lone Star Peptide, with cases filed in courts in California and Texas.
Retatrutide is still in Phase 3 clinical trials for obesity and type 2 diabetes and has not been approved by the FDA.
In June, the FDA stated that sales of retatrutide cannot lawfully be compounded or sold, and the agency has since sent at least 16 warning letters to companies marketing the drug.
The black market already exists at scale
Demand for retatrutide has boomed anyway, driven largely by social media attention around its trial results.
Some sellers advertise it openly as a "cutting edge therapy" that "outperforms today's leading medications," according to Lilly's lawsuit against Aesthetic Envy.
Other vendors list it as "for research use only" without a prescription, a label Lilly says is a cover for direct human consumption.
As recently as Aug. 8, two bodegas in Brooklyn were still displaying posters advertising the drug alongside other peptides.
Lilly says the products are sourced from "overseas manufacturers" and are entirely unverified.
US Customs and Border Protection intercepted over 690 shipments totaling more than 31,000 units of illicit GLP-1 drugs in fiscal year 2025.
In July alone, that figure more than doubled, with over 1,400 seizures and nearly 90,000 vials intercepted.
"What is being sold on the black market is not a medicine — it is entirely unverified, unapproved and not worth the risk."
Dr. David Hyman, Chief Medical Officer, Eli Lilly
Why Lilly is moving now
Lilly plans to submit retatrutide for US regulatory approval in the first quarter of 2027, targeting obesity, knee osteoarthritis pain, and sleep apnea.
Phase 3 data showed overweight or obese patients with type 2 diabetes lost an average of nearly 13% of their body weight after 80 weeks on a four-milligram dose.
Wall Street analysts expect retatrutide to be a blockbuster, but have flagged concern about the illicit market eating into future sales.
Lilly's own lawsuit against Striker Pharmacy states that consumers are already switching from approved Lilly medicines to illegal retatrutide products, citing lower cost and perceived superior efficacy.
Lilly has referred more than 200 individuals and entities to the FDA, the Justice Department, state attorneys general, and professional licensing boards.
The company is also calling on social media platforms, payment processors, credit card companies, and shipping firms to cut off illegal sellers.
The six lawsuits are a start, but Lilly's own executive acknowledged they won't solve the problem alone. The illegal market for retatrutide is global, and enforcement so far has produced few visible consequences.